NEW YORK, NY / ACCESSWIRE / August 29, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Diebold Nixdorf, Incorporated (DBD)
Investors Affected : February 14, 2017 - August 1, 2018
A class action has commenced on behalf of certain shareholders in Diebold Nixdorf, Incorporated. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) as a result of the Wincor acquisition and related integration, the Company was less focused on its core business; (2) the Company expected certain customers would not renew their service contracts (i.e. contract runoff); (3) the Company was not adequately prepared to staff service technicians; (4) as a result of the expected contract runoff, the Company would suffer a shortage of adequately trained service technicians; (5) as a result, the Company would suffer margin pressure in its services segment; (6) as a result of the foregoing, the Company would lose market share; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/diebold-nixdorf-incorporated-loss-submission-form/?id=3255&from=1
Karyopharm Therapeutics Inc (KPTI)
Investors Affected : on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.
A class action has commenced on behalf of certain shareholders in Karyopharm Therapeutics Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
Shareholders may find more information at https://securitiesclasslaw.com/securities/karyopharm-therapeutics-inc-loss-submission-form/?id=3255&from=1
Eagle Bancorp, Inc. (EGBN)
Investors Affected : March 2, 2015 - July 17, 2019
A class action has commenced on behalf of certain shareholders in Eagle Bancorp, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/eagle-bancorp-inc-loss-submission-form/?id=3255&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com: